Highbridge Capital Management’s Travere Therapeutics TVTX Stock Holding History

Highbridge Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-19,900	Closed	-$386K	–	1782
2017 Q2	$386K	Buy	+19,900	New	+$361K	0.01%	854
2016 Q2	–	Sell	-75,100	Closed	-$1.03M	–	1762
2016 Q1	$1.03M	Buy	75,100 +41,100	+121%	+$623K	0.02%	721
2015 Q4	$656K	Buy	34,000 +15,100	+80%	+$302K	0.01%	903
2015 Q3	$383K	Sell	18,900 -4,400	-19%	-$130K	0.01%	1141
2015 Q2	$773K	Buy	+23,300	New	+$638K	0.01%	804

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Highbridge Capital Management's TVTX Position: Q1 2019 in Review

Highbridge Capital Management sold out of Travere Therapeutics (TVTX) in Q1 2019, closing a stake of 65,146 shares — an estimated $1.47M sold.

Highbridge Capital Management first reported a position in TVTX in Q3 2015 and held it in 6 quarters. The position peaked at $3.48M in Q3 2018. 131 funds tracked by Wall St. Rank hold TVTX as of Q1 2019.

Highbridge Capital Management reported no remaining Travere Therapeutics position as of Q1 2019 after selling out during the quarter.
Highbridge Capital Management sold 65,146 Travere Therapeutics shares in Q1 2019, an estimated $1.47M.
Highbridge Capital Management first reported a position in Travere Therapeutics in Q3 2015 and held it in 6 quarters.
Highbridge Capital Management's Travere Therapeutics position peaked at $3.48M in Q3 2018.
131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2019.

Based on Highbridge Capital Management's 13F filing for Q1 2019, filed 15 May 2019.